A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms OPRA
Most Recent Events
- 04 Feb 2025 Planned End Date changed from 1 Nov 2024 to 1 Nov 2026.
- 04 Feb 2025 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2026.
- 01 Sep 2024 Results evaluating the ability of restaging MRI to predict oncologic outcomes and identify imaging features associated with residual disease (RD) after TNTpublished in the Radiology